share_log

Novavax | 8-K: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax | 8-K: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

諾瓦瓦克斯醫藥 | 8-K：Novavax 公佈2024年第三季度財務業績和運營亮點
美股SEC公告 ·  2024/11/12 22:40

Moomoo AI 已提取核心訊息

Novavax reported Q3 2024 total revenue of $85 million, down from $187 million YoY, with product sales of $38 million and licensing revenue of $46 million. The company ended the quarter with $1 billion in cash and receivables, while posting a net loss of $121 million, slightly improved from $131 million loss in Q3 2023.The company achieved significant milestones including FDA's removal of clinical hold on COVID-19-Influenza Combination vaccine trials and receiving U.S. FDA and European Commission authorizations for its updated 2024-2025 COVID-19 vaccine. Cost reduction initiatives showed progress with 26% decrease in combined R&D and SG&A expenses compared to Q3 2023.Novavax updated its full year 2024 guidance, lowering total revenue expectations to $650-700 million from previous $700-800 million, with product sales projected at $175-225 million. The company maintains its target of reducing annual operating expenses to approximately $350 million by 2026, representing an 80% reduction from 2022 levels.
Novavax reported Q3 2024 total revenue of $85 million, down from $187 million YoY, with product sales of $38 million and licensing revenue of $46 million. The company ended the quarter with $1 billion in cash and receivables, while posting a net loss of $121 million, slightly improved from $131 million loss in Q3 2023.The company achieved significant milestones including FDA's removal of clinical hold on COVID-19-Influenza Combination vaccine trials and receiving U.S. FDA and European Commission authorizations for its updated 2024-2025 COVID-19 vaccine. Cost reduction initiatives showed progress with 26% decrease in combined R&D and SG&A expenses compared to Q3 2023.Novavax updated its full year 2024 guidance, lowering total revenue expectations to $650-700 million from previous $700-800 million, with product sales projected at $175-225 million. The company maintains its target of reducing annual operating expenses to approximately $350 million by 2026, representing an 80% reduction from 2022 levels.
諾瓦瓦克斯醫藥報告2024年第三季度總營業收入爲8500萬，較去年同期的18700萬下降，產品銷售爲3800萬，許可收入爲4600萬。公司在本季度末持有現金和應收款項10億，同時公佈淨虧損12100萬，較2023年第三季度的13100萬虧損有所改善。公司達成了重要里程碑，包括FDA解除COVID-19與流感組合疫苗試驗的臨牀持有狀態，並獲得美國FDA和歐洲委員會對其更新的2024-2025年COVID-19疫苗的授權。成本削減措施取得進展，研發及銷售和行政（SG&A）費用較2023年第三季度下降了26%.諾瓦瓦克斯醫藥更新了2024年全年指引，將總營業收入預期下調至65000-70000萬，之前預期爲70000-80000萬，產品銷售預期爲17500-22500萬。公司維持到2026年將年度營業費用減少至約35000萬的目標，較2022年的水平減少80%。
諾瓦瓦克斯醫藥報告2024年第三季度總營業收入爲8500萬，較去年同期的18700萬下降，產品銷售爲3800萬，許可收入爲4600萬。公司在本季度末持有現金和應收款項10億，同時公佈淨虧損12100萬，較2023年第三季度的13100萬虧損有所改善。公司達成了重要里程碑，包括FDA解除COVID-19與流感組合疫苗試驗的臨牀持有狀態，並獲得美國FDA和歐洲委員會對其更新的2024-2025年COVID-19疫苗的授權。成本削減措施取得進展，研發及銷售和行政（SG&A）費用較2023年第三季度下降了26%.諾瓦瓦克斯醫藥更新了2024年全年指引，將總營業收入預期下調至65000-70000萬，之前預期爲70000-80000萬，產品銷售預期爲17500-22500萬。公司維持到2026年將年度營業費用減少至約35000萬的目標，較2022年的水平減少80%。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 3.080
    Camp4 Therapeutics
    CAMP
    -- 6.250
    Channel Therapeutics
    CHRO
    -- 2.460
    Allakos
    ALLK
    -- 1.060
    Exicure
    XCUR
    -- 12.3600
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啓，全球股市新風口在哪裏？
    ▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？ 展开
    離川普上臺只有7天了～